The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
htTps://www.sciencedirect.com/science/article/pii/S1359610120301647
CW for me it is property and later this year banks.
I think we have yet to see the buy opportunity for Barclays and LLOY yet. I figure Nov / Dec and hold for 5 years.
As for our short term focus, I hope they take the money and run. LOXL2 is an interesting opportunity but we only have 17%. The data bank is worth money as well and would be well used by a major.
I see any takeover would be between £300m to £500m.
I know other will think more, but in today’s world I think these numbers are achievable.... subject to good results !!
CW25 I think a clean take over would be best for all. I know they don’t happen much on aim, but for all holders here I believe it would be the best opportunity for quick return. We can then invest in the many opportunities outside of pharma.
CW25
I added late Friday another 18k.
If we drop below 35p I will add a further 20k shares.
I am targeting an additional 50k pre news.
I will not add post news. I am now hoping Richard is combining the COPD and C-19 Hospital trials to generate sufficient data to make a emergency application to the FDA and MHRA.
I got the impression when i had limited communication with the company a few months back that they were keen to hand over the day to day as soon as Synairgen had de-risked as much of the process as possible.
I would imagine the FDA would listen to a AZ or GSK or McKesson more than little Synairgen.
You know my ultimate is a deal is reached an it is all wrapped into one RNS. That takes away the pain of deciding when to sell. I would take £3+ per share happily.
Has anyone researched what a drug sells for ?
Did anyone listen to Richard Marsden’s interview from the German tradeshow.
I get it, the share price is low, however we know why. An institution is clearing, just like they are with all their other shares they acquired from Woodford.
So the price is back at 35p. The placing level. For me this represents further opportunity to buy as I think SNG001 works. For others they will sell, that is there choice.
But anyone researching this will know the true value of SNG001 is multiples of the current MCAP, if it works for COPD, add in C-19 and things get very interesting.
So this board is going to be full of sceptical investors, trolls and investors that believe. Should make a fully rounded overview.
I know one thing. I have funds and will be adding. You make your own minds up.... and try not to be influenced by anyone here !!
This is the MM clearing.
They have dropped it to clear a large lump. We should see a large trade printed soon ! IMO !
Acacia dumped a few more and offered a very attractive buy / top up that those that fancied a nibble. I did !
Well I’m sure many would have expected the share to be testing new highs as we enter mid July. However as we know this share has been quite testing over the months. Griff then Lansdowne and now Acacia.
Time to sit on your hands and not react.... unless you want to obviously!
Some chunky buys now showing.
I’m expecting a large trade to land tomorrow!!
Have a cracking evening all.
Wow you wrote that with full CAPS. Anger management classes required for you.
Calm Warwick you did just troll every Covid Share literally 5 minutes ago, or was that your other side ? Lol
Relax
Chrishar just read the latest report and feeling very positive this PM. Code 6 as well (what ever that might be).
Very exciting weeks ahead.
Anyone want to be out of this over the weekend.... let alone tonight ??
Well with two phase 2 studies about to land and the share price only slightly above the 8 year average, personally I think if you believe, this offers amazing value.
Obviously there are risks to every investment on AIM and the trolls will only focus on the negatives.
16 days + 40mins trading in July left !!!
Positive 3rd party data keeps landing !!
https://www.sciencedirect.com/science/article/pii/S1359610120301647
Boom
Time soon ??
Only invest what you can afford ....
The COPD trial covers multiple data points against a range of virus. This data is significant and will hugely support any emergency application across multiple agencies.
Anyone suggesting Richard Marsden is sitting on the full data set from this trial is mistaken.
The emergency regulatory application is the most critical part of this journey, approval would be gold.
The Merck news this evening is equally positive and will add further weight behind our application.
SNG001 is safe, we know that as it can be used at home. Next step is to understand the efficacy. For me anything above 40% success rate would be a huge result.
We have so many reports and research data supporting Interferon now, our surveillance data gather will be huge.
Exciting times for all. I know some are struggling with the low share price, lack of news, competitor stories.... but our time is close. 17 trading days left in July.
Oh as for the home study, I think it will be opened up and the. Immediately expanded onto a international platform as part of any partnership deal. Personally I see the FDA approving SNG001 ahead of the MHRA. I am looking to the US for the future and partner here.
Good luck all
Just in case you missed it
https://www.pharmaceutical-technology.com/features/covid-19-synairgen-virtual-clinical-trials/
I agree this is extremely positive.
Overlay that with the latest interview from this morning and the story gains further weight.
Had you read the report you would see the last update date was May.
The CEO has subsequently in a number of interviews confirmed C-19 hospital results will be this month. COPD will be released in Summer.
Why do people on here always try and find a negative of change facts to fiction ?
https://www.pharmaceutical-technology.com/features/covid-19-synairgen-virtual-clinical-trials/